Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.
BCR::ABL1 digital PCR
chronic myeloid leukemia
treatment‐free remission
tyrosine kinase inhibitor discontinuation
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
12 Jul 2024
12 Jul 2024
Historique:
revised:
22
06
2024
received:
19
04
2024
accepted:
24
06
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
12
7
2024
Statut:
aheadofprint
Résumé
Precise and reliable predictive parameters to accurately identify chronic myeloid leukemia (CML) patients who can successfully discontinue their tyrosine kinase inhibitor (TKI) treatment are lacking. One promising parameter is depth of molecular response measured by BCR::ABL1 digital PCR (dPCR). The aim of this study was to validate a previously described prediction cutoff of 0.0023%
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.
Références
Bower H, Björkholm M, Dickman PW, Höglund M, Lambert PC, Andersson TML. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851‐2857.
Maas CCHM, van Klaveren D, Ector GICG, et al. The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in The Netherlands, 1989–2018. Br J Haematol. 2022;196(5):1219‐1224.
Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO‐SKI): a prespecified interim analysis of a prospective, multicentre, non‐randomised, trial. Lancet Oncol. 2018;19(6):747‐757.
Dulucq S, Astrugue C, Etienne G, Mahon FX, Benard A. Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta‐analysis of studies over the last ten years. Br J Haematol. 2020;189(3):452‐468.
Scott S, Cartwright A, Francis S, et al. Assessment of droplet digital polymerase chain reaction for measuring BCR‐ABL1 in chronic myeloid leukaemia in an international interlaboratory study. Br J Haematol. 2021;194(1):53‐60.
Basu AS. Digital assays part I: partitioning statistics and digital PCR. SLAS Technol. 2017;22(4):369‐386.
Mori S, Vagge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90(10):910‐914.
Lee SE, Choi SY, Song HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101(6):717‐723.
Nicolini FE, Dulucq S, Boureau L, et al. Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping Imatinib first‐line in chronic phase CML patients. Clin Cancer Res. 2019;25:6606‐6613.
Bernardi S, Malagola M, Zanaglio C, et al. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Med. 2019;8(5):2041‐2055.
Colafigli G, Scalzulli E, Porrazzo M, et al. Digital droplet PCR at the time of TKI discontinuation in chronic‐phase chronic myeloid leukemia patients is predictive of treatment‐free remission outcome. Hematol Oncol. 2019;37(5):652‐654.
Atallah E, Schiffer CA, Radich JP, et al. Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial. JAMA Oncol. 2021;7(1):42‐50.
Lu L, Kok CH, Dang P, et al. Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment‐free remission. Br J Haematol. 2022;198(3):600‐603.
Perusini MA, Novitzky‐Basso I, Atenafu EG, et al. Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: treatment‐free remission accomplished by dasatinib (TRAD) study. Br J Haematol. 2023;203(5):781‐791.
Kim DDH, Novitzky‐Basso I, Kim TS, et al. Optimal duration of imatinib treatment/deep molecular response for treatment‐free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial. Br J Haematol. 2021;193(4):779‐791.